Current Topics in Esophageal Squamous Cell Carcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2020 Oct 14

PMID 33050257

Citations 5

Authors

Hiroki Kurumi

Hajime Isomoto

Affiliations

Soon will be listed here.

Abstract

Esophageal squamous cell carcinoma (ESCC) is one of the most deadly cancers due to its extremely aggressive nature and poor survival rate. Central to East Asia is one of regions with the highest incidence of ESCC. In these five papers, the international leaders of ESCC in Asia have taken various approaches to ESCC. Lin et al. compared intensity-modulated radiation therapy with three-dimensional stereoscopic radiation therapy with respect to treatment of ESCC. Song et al. demonstrated that (S)-10-Hydroxycamptothecin is useful in the ESCC cell lines as well as in vivo using a patients-derived xenograft tumor model in mice. Chen et al. showed Stromal cell-derived factor-1α expression is an independent prognostic predictor of ESCC. Lin et al. showed that the SUV/SUV ratio of PET-CT was associated with ESCC prognosis. Yoon et al. investigated the association between sarcopenia and prognosis in the ESCC patients. All reports are an essential approach to overcoming ESCC.

Citing Articles

Analysis of the influencing factors in the long-term survival of esophageal cancer.

Rui W, Li C, Da Q, Yue Y, Jing L, Ruirui G Front Oncol. 2024; 13:1274014.

PMID: 38304026 PMC: 10833228. DOI: 10.3389/fonc.2023.1274014.

Single-cell transcriptomics reveals heterogeneity in esophageal squamous epithelial cells and constructs models for predicting patient prognosis and immunotherapy.

Li C, Song W, Zhang J, Luo Y Front Immunol. 2023; 14:1322147.

PMID: 38098487 PMC: 10719955. DOI: 10.3389/fimmu.2023.1322147.

The predicting role of serum tumor-specific growth factor for prognosis of esophageal squamous cell carcinoma.

Xu X, Wang W, Tian B, Zhang X, Ji Y, Jing J BMC Cancer. 2023; 23(1):1067.

PMID: 37932676 PMC: 10626642. DOI: 10.1186/s12885-023-11602-x.

PRR11 in Malignancies: Biological Activities and Targeted Therapies.

Han W, Chen L Biomolecules. 2022; 12(12).

PMID: 36551227 PMC: 9775115. DOI: 10.3390/biom12121800.

CircRNA circ_0023984 promotes the progression of esophageal squamous cell carcinoma via regulating miR-134-5p/cystatin-s axis.

Yang G, Zhang Y, Lin H, Liu J, Huang S, Zhong W Bioengineered. 2022; 13(4):10578-10593.

PMID: 35440286 PMC: 9161969. DOI: 10.1080/21655979.2022.2063562.

References

Gertler R, Stein H, Langer R, Nettelmann M, Schuster T, Hoefler H . Long-term outcome of 2920 patients with cancers of the esophagus and esophagogastric junction: evaluation of the New Union Internationale Contre le Cancer/American Joint Cancer Committee staging system. Ann Surg. 2011; 253(4):689-98. DOI: 10.1097/SLA.0b013e31821111b5. View

Pommier Y . DNA topoisomerase I inhibitors: chemistry, biology, and interfacial inhibition. Chem Rev. 2009; 109(7):2894-902. PMC: 2707511. DOI: 10.1021/cr900097c. View

Xu D, Li G, Li H, Jia F . Comparison of IMRT versus 3D-CRT in the treatment of esophagus cancer: A systematic review and meta-analysis. Medicine (Baltimore). 2017; 96(31):e7685. PMC: 5626151. DOI: 10.1097/MD.0000000000007685. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2018; 48(1):16-31. PMC: 6322506. DOI: 10.1093/ageing/afy169. View

Arnold M, Soerjomataram I, Ferlay J, Forman D . Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 2014; 64(3):381-7. DOI: 10.1136/gutjnl-2014-308124. View

Wu T, Yang Y, Zhu S, Shi M, Su H, Wang Y . Risk-adapted survival benefit of IMRT in early-stage NKTCL: a multicenter study from the China Lymphoma Collaborative Group. Blood Adv. 2018; 2(18):2369-2377. PMC: 6156886. DOI: 10.1182/bloodadvances.2018021311. View

Huang J, Xu B, Liu Y, Huang J, Lu P, Ba Y . Irinotecan plus S-1 versus S-1 in patients with previously treated recurrent or metastatic esophageal cancer (ESWN 01): a prospective randomized, multicenter, open-labeled phase 3 trial. Cancer Commun (Lond). 2019; 39(1):16. PMC: 6444575. DOI: 10.1186/s40880-019-0359-7. View

Lee N, Xia P, Quivey J, Sultanem K, Poon I, Akazawa C . Intensity-modulated radiotherapy in the treatment of nasopharyngeal carcinoma: an update of the UCSF experience. Int J Radiat Oncol Biol Phys. 2002; 53(1):12-22. DOI: 10.1016/s0360-3016(02)02724-4. View

Pommier Y . Drugging topoisomerases: lessons and challenges. ACS Chem Biol. 2012; 8(1):82-95. PMC: 3549721. DOI: 10.1021/cb300648v. View

10.

Kudo T, Hamamoto Y, Kato K, Ura T, Kojima T, Tsushima T . Nivolumab treatment for oesophageal squamous-cell carcinoma: an open-label, multicentre, phase 2 trial. Lancet Oncol. 2017; 18(5):631-639. DOI: 10.1016/S1470-2045(17)30181-X. View

11.

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

12.

Quante M, Tu S, Tomita H, Gonda T, Wang S, Takashi S . Bone marrow-derived myofibroblasts contribute to the mesenchymal stem cell niche and promote tumor growth. Cancer Cell. 2011; 19(2):257-72. PMC: 3060401. DOI: 10.1016/j.ccr.2011.01.020. View

13.

Guleng B, Tateishi K, Ohta M, Kanai F, Jazag A, Ijichi H . Blockade of the stromal cell-derived factor-1/CXCR4 axis attenuates in vivo tumor growth by inhibiting angiogenesis in a vascular endothelial growth factor-independent manner. Cancer Res. 2005; 65(13):5864-71. DOI: 10.1158/0008-5472.CAN-04-3833. View

14.

Yang L, Hong J, Di J, Guo Y, Han M, Liu M . 10-Hydroxycamptothecin (HCPT) nanosuspensions stabilized by mPEG-HCPT conjugate: high stabilizing efficiency and improved antitumor efficacy. Int J Nanomedicine. 2017; 12:3681-3695. PMC: 5439984. DOI: 10.2147/IJN.S134005. View